

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/774,176-Conf. #7186
<i>(Use as many sheets as necessary)</i>				Filing Date	February 6, 2004
				First Named Inventor	Miles W. Carroll
				Art Unit	1644
				Examiner Name	M. DiBrino
Sheet	1	of	1	Attorney Docket Number	31127/43656C

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
					T <sup>6</sup>

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/M.D./	C1	Oxford BioMedica announces data safety monitoring board recommendation to continue TroVax® phase III trist study. Achievement triggers €10 million milestone payment from Sanofi-Aventis. News 2008/OB/04, February 20, 2008.			
	C2	Oxford BioMedica Completes patient recruitment for phase III TRIST study of TroVax® in renal cancer. New 2008/OB/06, March 10, 2008.			
	C3	Amato et al., Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax®): a phase II trial. TAT Meeting 2008, 2008/OB/09 abstract, Oxford BioMedica Ltd, Oxford, U.K. March 18, 2008.			
	C4	Oxford BioMedica Report encouraging new phase II trial results with TroVax® in prostate cancer. News 2008/OB/09, March 25, 2008.			
	C5	Oxford BioMedica announces TroVax® phase II trial results in renal cancer to be presented at ASCO. News 2008/OB/14, May 16, 2008.			
	C6	Sanofi-Aventis and Oxford BioMedica report encouraging TroVax® phase II trial results in metastatic renal cancer. News 2008/OB/17, June 2, 2008.			
	C7	Oxford BioMedica announces data safety monitoring board recommendation for TroVax® phase III TRIST study. News 2008/OB/21. July 11, 2008.			
	C8	Oxford BioMedica received commitment or independent phase III trial of TroVax® in adjuvant colorectal cancer. News 2008/OB/22, July 14, 2008.			
	C9	Oxford BioMedica reports further data from interim review of TroVax® phase III TRIST study. News 2008/OB/23, July 15, 2008.			
	/M.D./	C10	McDonald, Letter to investigator, TV3/001/06: An international, randomized, double blind, placebo controlled, parallel group study to investigate whether TroVax®, added to first-line standard of care therapy, prolongs the survival of patients with locally advanced or metastatic clear cell renal adenocarcinoma (TRIST)July 15, 2008.		

Examiner Signature	/Marianne DiBrino/	Date Considered	01/27/2009
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.